Lilly's Basaglar, Crestor Generics Helped Hold Down Drug Spending Growth In 2017
Executive Summary
Express Scripts' annual drug trend report highlights impact of key follow-on launches, and its own management solutions programs, in limiting the growth in overall drug spending for commercial plans to 1.5%; forecast calls for double-digit growth in inflammatory category to continue at least the next three years until biosimilar savings kick in.
You may also be interested in...
Prime Therapeutics Expanding Formulary Exclusion Program In 2018
The NetResults formulary contributed to a 0.2% decline in overall drug spending by the pharmacy benefit manager's commercial clients in 2017, according to Prime Therapeutics' Drug Trend report.
Lilly/BI's Basaglar: A Rosier Outlook For US Biosimilars?
Sales of the insulin glargine product in its first full year on the market were strong at $432.1m, but Lilly said it is offering steep rebates in exchange for market access and it's not clear that the growth is sustainable if more copies enter the market.
Pfizer Sets The Stage For A Biosimilar Showdown Over Exclusive Contracts
Pfizer filed a lawsuit against J&J over its efforts to block sales of Pfizer's biosimilar Inflectra through exclusive contracting for Remicade. The suit claims J&J coerced payers by vowing to withhold all Remicade rebates if any Inflectra is reimbursed. J&J says Pfizer has failed to show the value of Inflectra.